Drug Profile
Research programme: monoclonal antibodies - Genus Oncology
Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator Genus Oncology
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 31 Aug 2023 Discontinued - Preclinical for Cancer in USA (Parenteral), prior to August 2023 (Genus Oncology website, August 2023)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 26 Feb 2016 Preclinical trials in Cancer in USA (Parenteral)